AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study of an Extended Release (ER) Tablet, Single and Repeated Dosing
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: AZD1305Drug: Placebo
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 94
- Registration Number
- NCT00689039
- Locations
- 🇸🇪
Research Site, Göteborg, Sweden
Study to Compare Different Formulations of AZD3355
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00688402
- Locations
- 🇸🇪
Research Site, Varvsgatan, Lulea, Sweden
Regional Observatory on Metabolic Syndrome- LAZIO
Completed
- Conditions
- Metabolic Syndrome
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1574
- Registration Number
- NCT00689455
- Locations
- 🇮🇹
Research Site, Viterbo, Italy
Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: AZD1305
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT00689403
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: AZD1305
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT00689247
- Locations
- 🇬🇧
Research Site, Macclesfield, Cheshire, United Kingdom
Single Ascending Dose Study (SAD) iv Formulation
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: AZD1305Drug: Placebo
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00688831
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapineXR® and Other Atypical Antipsychotics
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-10-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 158
- Registration Number
- NCT00689325
- Locations
- 🇳🇱
Research Site, Zwolle, Netherlands
Study to Investigate Safety and Tolerability of a Single Dose of AZD6482
Phase 1
Completed
- Conditions
- Antiplatelet Effect
- Interventions
- Drug: AZD6482Drug: Placebo
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2008-06-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT00688714
Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention
Completed
- Conditions
- Peripheral Arterial Disease (PAD)Moderate Risk for Cardiovascular Disease (CVD)
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2012-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9000
- Registration Number
- NCT00689377
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
Phase IIA Study in Patients With Schizophrenia
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 106
- Registration Number
- NCT00686998
- Locations
- 🇺🇸
Research Site, Rockville, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath